CDK2-IN-41
CDK2-IN-41 (Compound 7a) is a CDK2 inhibitor that exerts anticancer activity by binding to CDK2, thereby inhibiting the cell cycle, inducing cytotoxicity, promoting ROS production, and triggering Apoptosis. CDK2-IN-41 exhibits an IC50 of 10 µM against acute myeloid leukemia (AML) HL-60 cells. It holds potential for research in AML-related cancer therapy[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; CDK; Reactive Oxygen Species (ROS)
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Field of Research
Cancer
Smiles
N#CC1=C2C(CNCC2)=C(C=C1N3CCCCC3)C4=CC=CS4
Molecular Formula
C19H21N3S
Molecular Weight
323.46
References & Citations
[1]Ananta, et al. Design, Synthesis, and Simulation of Functionalized 1, 2, 3, 4‐Tetrahydroisoquinolines to Treat Acute Leukemia Cells[J]. ChemistrySelect, 2025, 10 (7) : e202404024.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
